Moolec Science SA Ordinary Shares logo

Moolec Science SA Ordinary Shares(MLEC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.85
11/10/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MLEC

11/10/2026: MLEC (1-star) is currently NOT-A-BUY. Pass it for now.

Moolec Science SA is a development-stage biotechnology company specializing in molecular farming to produce animal proteins in plants. Its primary strengths lie in its proprietary technology platform and innovative pipeline products like Piggy Sooy and GLASO. The core investment story centers on capturing long-term growth in the sustainable alternative protein market through cost-effective crop production. However, investors face notable execution, regulatory, and dilution risks due to early-stage commercialization and recurring operating losses. The stock is best suited for growth-oriented investors with high risk tolerance who are willing to monitor regulatory milestones and capital-raising updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential through innovative molecular farming, but commercialization is still at an early stage.
Momentum investorStrong fit while signal remains positiveLow market float and high beta can spark sharp short-term momentum moves when positive sector catalysts emerge.
Value investorWeak fitThe lack of consistent earnings and ongoing net losses make it unsuitable for traditional value investing.
Dividend investorWeak fitThe company pays no dividends as capital is entirely reinvested into research and development.
Low-risk investorWeak fitHigh price volatility, regulatory uncertainties, and developmental risk create significant exposure for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading liquidity and small market capitalization lead to sharp daily price fluctuations.
Valuation riskHighValuations rely heavily on long-term future market assumptions rather than current earnings or cash flows.
Competition risk (alternative protein & ag-tech competition)Medium / highThe alternative food tech landscape features intense rivalry from both plant-based and cellular agriculture innovators.
Business qualityMediumProprietary molecular farming technology is promising, but the business model remains unproven at global scale.
Dividend incomeLow / noneNo dividend yields are offered, rendering the stock purely a capital appreciation play.
Execution riskHighSuccess depends on complex scale-up processes, successful field trials, and securing necessary regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 0.62M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 67.1K shares
Beta -0.32
52 Weeks Range 0.80 - 23.22
Updated Date 11/15/2026
52 Weeks Range 0.80 - 23.22
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -199.02

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -41.41%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/10/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MLEC receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MLEC has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+5830.7%) is partially offset by negative earnings growth (-1424.3%), weak cash generation (FCF margin -9.0%), weak profitability (net margin -33.4%).

Financial Health Rating

★★★★★
MLEC's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 37.3% of revenue). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is MLEC's strongest growth driver at +5830.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-1424.3%, negative) and free-cash-flow growth (-217.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.1% and approximately 123.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 21.06% supports management-shareholder alignment.

Top 5 Institutional Investors

UBS Group AG 0.06%
Caitong International Asset Management Co., Limited. 0.00%
SBI Securities Co Ltd 0.00%
HRT FINANCIAL LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
MLEC generates approximately $342 of gross profit, $-31 of operating income, and $-90 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 34.44%

Quantitative Style Profile

★★★★★
MLEC has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Seed and Integrated ProductsCommercialization of specialized seed lines, grain output, and ingredient prototypes derived from molecular farming platforms.The primary avenue through which the company intends to commercialize its engineered crops and functional food components.
Geographic Operations (Latin America & International)R&D facilities, agricultural field testing, and operational hubs primarily based in Argentina and the United States.Leverages rich agricultural regions for cost-effective field production and scaling of genetically engineered plants.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 66.02M
Price to Sales(TTM) -
Enterprise Value 66.02M
Price to Sales(TTM) -
Enterprise Value to Revenue 0.19
Enterprise Value to EBITDA -1.01
Shares Outstanding 726.12K
Shares Floating 897.82K
Shares Outstanding 726.12K
Shares Floating 897.82K
Percent Insiders 21.06
Percent Institutions 0.07

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.